Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Continued improvement in cardi...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis

Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis

Bibliographic Details
Main Authors: Pennell, D., Porter, J., Cappellini, M., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M., Kattamis, A., Smith, G., Habr, D., Roubert, B., Taher, A.
Format: Article
Published: Ferrata Storti Foundation 2010
Subjects:
R Medicine
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
    by: Pennell, D., et al.
    Published: (2010)
  • Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
    by: Pennell, D.J., et al.
    Published: (2010)
  • Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C
    by: Cappellini, M.D., et al.
    Published: (2010)
  • Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
    by: Dudley J. Pennell, et al.
    Published: (2011-01-01)
  • Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major
    by: Khaled M. Musallam, et al.
    Published: (2011-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs